On March 25th MBBP client Atrium Medical Corporation announced it had received positive results for its clinical trial of its infusion catheter. The study is a multi-center, multinational clinical trial conducted to determine the optimal treatment for patients with an acute anterior wall myocardial infarction (heart attack).
When patients have suffered a heart attack, recovery of the heart muscle is often suboptimal, despite restoration of blood flow. The trial of Atrium’s ClearWay RX Local Therapeutic Infusion Catheter device was designed to demonstrate whether therapies are able to reduce “infarct size in patients with large heart attacks who have the greatest clinical need.” The trial consisted of 452 patients and was conducted at 37 clinical sites in the United States and five European countries.
For more information, please see the article in Mass High Tech.